Belatacept
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Proteinuria
Conditions
Proteinuria
Trial Timeline
Oct 1, 2015 → Oct 1, 2020
NCT ID
NCT02327403About Belatacept
Belatacept is a phase 2 stage product being developed by Bristol Myers Squibb for Proteinuria. The current trial status is completed. This product is registered under clinical trial identifier NCT02327403. Target conditions include Proteinuria.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00719225 | Pre-clinical | Completed |
| NCT02939365 | Approved | Withdrawn |
| NCT03375138 | Phase 1 | Completed |
| NCT02327403 | Phase 2 | Completed |
| NCT01953120 | Approved | Completed |
| NCT01791491 | Phase 2 | Completed |
| NCT01496417 | Pre-clinical | Completed |
| NCT01033500 | Pre-clinical | Withdrawn |
| NCT00578448 | Phase 2 | Completed |
Competing Products
6 competing products in Proteinuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zibotentan/Dapagliflozin + Dapagliflozin | AstraZeneca | Phase 2 | 52 |
| candesartan cilexetil | AstraZeneca | Phase 3 | 77 |
| Zibotentan/Dapagliflozin + Dapagliflozin | AstraZeneca | Phase 3 | 77 |
| valsartan | Novartis | Approved | 85 |
| Sparsentan | Travere Therapeutics | Approved | 80 |
| Losartan Potassium + Comparator: amlodipine besylate + Enalapril Maleate | Organon | Phase 3 | 72 |